Top Arecoline Secrets
MI-CP151 was a stage 1b randomised, double-blind, placebo managed, dose-escalation, multicentre study to evaluate a number of intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Primary trial targets had been To guage the safety and tolerability of sifalimumab in dermatomyositis or polymyositis